Loading quotes...

Forecast

The analysts' average price target is €8.71 (+59,557.53%). The median is €8.93 (+61,064.38%).

Buy	4
Hold	6
Sell	5

News Go to news feed

Labcorp raises full-year outlook and focuses on hospital partnerships

Labcorp raised its full-year revenue growth forecast to 7.5–8.6% and expects about 8% growth in its diagnostics business, roughly half organic and half inorganic. The acquisition of Invitae is expected to strengthen the second half and boost the unit’s revenue by about 10%; the deal is seen as slightly accretive. The company targets annual cost savings of USD 100–125 million and anticipates margin improvements, but flags regulatory risks such as possible changes to the ACA/Medicaid and an expected PMM-related charge of around USD 100 million. The focus remains on strategic hospital deals, biopharma services and innovations in women's health, oncology, neurology and autoimmune diseases. » More on de.investing.com

Financials

In the last year, Invitae had revenue of €481.32m and net profit of -€2.9bn

(EUR)	2022	YoY
Revenue	481.32m	18.87%
Gross profit	92.34m	6.07%
Net profit	-2.9bn	768.85%
EBITDA	-2.7bn	975.23%

Fundamentals

Metric	Value
Market capitalization	€4.86m
Number of shares	286.49m
52-week high/low	€2.09 - €0.0134
Dividends	No
Beta	1.59
P/E ratio	0.00
PEG ratio	0.00
P/B ratio	0.04
P/S ratio	0.01

Company profile

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.